The Center for Drug Design (CDD) in collaboration with the University of Minnesota Technology Commercialization team, and our industry Licensee, TOPIX Pharmaceuticals, Inc., held a mini-symposium where attendees engaged in a scientific discussion on ProteXidine's journey from lab to market. ProteXidine is a proprietary biomimetic decoy molecule enhances skin's natural ability to mitigate damage caused by UV exposure and Reactive Oxygen Species (ROS). Ongoing scientific research continues to reveal promising new applications.  ProteXidine®: The Intersection of Science, Technology, and Skin-Aging.

The symposium was held on Thursday, April 10, 2025 at McNamara Alumni Center in Minneapolis, MN.

Symposium speakers included board-certified dermatologist and dermatologic surgeon , Dr. Naiem Issa and Vice President of Research and Development at TOPIX Pharmaceuticals, Steve Hernandez.  

Please visit our YouTube channel to view the presentation.